Marvin R. Garovoy, MD
Acting Chief Medical Officer

Dr. Garovoy is responsible for directing the worldwide clinical activities for all products at AceLink Therapeutics. Dr. Garovoy has over 20 years of experience in the Biopharmaceutical Industry with a successful track record of drug development. Prior to joining the company Dr. Garovoy helped develop Raptiva with XOMA/Genentech and held numerous positions in industry including Vice President of Clinical Science at Xoma, Sr. VP Clinical Development at Hyperion and Chief Medical Officer at Arriva Pharmaceuticals and Medgenics Inc. For the past six years he has been a Clinical Consultant for immunological/inflammatory diseases, metabolic rare diseases and gene therapy to which he has applied his translational medicine knowledge.  He obtained his undergraduate degree in Biology at New York University and received his M.D., with honors, at State University of New York Downstate Medical Center. He completed his residency in Internal Medicine at New York University, Bellevue Hospital and a Fellowship in Immunology, Transplantation and Nephrology at Harvard Medical School, Peter Bent Brigham Hospital. Dr. Garovoy is a member of the American Board of Internal Medicine. He holds medical licenses in New York, Massachusetts, Texas and California. He holds two patents: one for making universal donor cells and the second for psoriasis therapy (Genentech). Dr. Garovoy has published over 200 original articles and chapters and has held multiple teaching positions initially at Harvard Medical School and more recently as a faculty member at UCSF where he was Professor of Surgery, Medicine and Laboratory Medicine.

© Copyright AceLink Therapeutics. All rights reserved